Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Rare Diseases

Melanoma

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Temozolomide

Imatinib Mesylate

Antineoplastic Agents, Alkylating

Alkylating Agents

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Gleevec

Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle.

Temodar

Leslie Fecher, MD

tara mitchell, MD

This study has been designed to evaluate the side effects of Gleevec when given in combination with Temzolomide; and to learn more about how these drugs work in the body and whether this combination is useful in treating patients with melanoma.

Study of Temzolomide and Gleevec in Advanced Melanoma

Phase I/II Study of Temozolomide and Gleevec (Imatinib Mesylate, Formerly Known as STI571) in Advanced Melanoma

Number of reported grade 3 or 4 adverse events

Novartis Pharmaceuticals

Abramson Cancer Center at Penn Medicine

Gleevec + Temozolomide: Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle. Gleevec (600 mg) daily.

Arm A:

Age, Categorical

Sex: Female, Male

Race (NIH/OMB)

United States

Region of Enrollment

Tara C Mitchell

Data from final 4 patients enrolled on study not available

Safety - Grade 3 or 4 Adverse Events

4 subjects did not meet physician criteria for response rate, thus their data was unusable

Response

To Evaluate the Secondary Endpoints of Time to Disease Progression, Duration of Response, and Overall Survival of Patients Receiving Gleevec + Temozolomide

Overall Study

Spots Global Cancer Trial Database for temzolomide

Every month we try and update this database with for temzolomide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for temzolomide

Every month we try and update this database with for temzolomide cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for temzolomide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.